Liquidia Technologies Inc (LQDA) Peer Comparison
$67.85
$1.42
(2.13%)
As on 22-Sep-2026 13:37EDT
Market cap
$5,986 Mln
Revenue (TTM)
$451 Mln
P/E Ratio
47.8
P/B Ratio
31.4
Div. Yield
0 %
Edit
| Liquidia Technologies Inc (LQDA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | Elanco Animal Health (ELAN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
5,986 | 13,022 | 11,922 | 10,884 | 11,361 |
Revenue ($ Mln) |
451 | 692 | 831 | 777 | 5,020 |
Net Profit ($ Mln) |
138.61 | -696.24 | 54.90 | -191.64 | -199.00 |
Net Margin (%) |
30.74 | -100.64 | 6.61 | -24.68 | -3.96 |
RoE (%) |
115.57 | -- | 8.11 | -223.36 | -3.03 |
Price to Earnings |
47.77 | -- | 245.09 | -- | -- |
Price-To-Book |
31.36 | 123.68 | 16.92 | 134.74 | 1.73 |
Income Statement ($ Mln)
| Liquidia Technologies Inc (LQDA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | Elanco Animal Health (ELAN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
450.91 | 691.84 | 830.81 | 776.57 | 5,020.00 |
|
Cost of Revenue
|
33.93 | 47.45 | 14.09 | 52.53 | 2,380.00 |
|
Gross Profit
|
145.08 | 473.81 | 748.43 | 591.02 | 2,050.00 |
|
Operating Expenses
|
248.41 | 1,187.86 | 810.32 | 912.58 | 2,178.00 |
|
Operating Profit (EBIT)
|
168.58 | -543.47 | 6.41 | -188.54 | 462.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
149.50 | -706.17 | 26.37 | -191.09 | -166.00 |
|
Provision for Tax
|
10.90 | -7.73 | -35.26 | 0.56 | 33.00 |
|
Profit after Tax (Net Income)
|
138.61 | -696.24 | 54.90 | -191.64 | -199.00 |
|
Minority Interest
|
0.00 | 10.15 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Liquidia Technologies Inc (LQDA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | Elanco Animal Health (ELAN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
195.11 | -2,515.22 | 705.78 | 83.30 | 6,588.00 |
|
Minority Interest
|
0.00 | 10.15 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
137.51 | 2,832.54 | 29.12 | 217.70 | 5,121.00 |
|
Current Liabilities
|
189.30 | 890.65 | 153.80 | 460.45 | 1,852.00 |
|
Total Liabilities
|
327.93 | 936.03 | 836.65 | 689.81 | 13,358.00 |
Assets ($ Mln)
| Liquidia Technologies Inc (LQDA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | Elanco Animal Health (ELAN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
84.21 | 124.16 | 449.03 | 104.88 | 9,764.00 |
|
Current Assets
|
437.71 | 1,093.14 | 439.68 | 656.57 | 3,797.00 |
|
Total Assets
|
327.93 | 936.03 | 836.65 | 689.81 | 13,358.00 |
|
Total Debt*
|
128.94 | 2,493.78 | 9.42 | 219.21 | 3,918.00 |
|
Net Current Assets
|
248.41 | 202.49 | 285.87 | 196.12 | 1,945.00 |
Cashflow ($ Mln)
| Liquidia Technologies Inc (LQDA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | Elanco Animal Health (ELAN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-35.69 | -445.91 | 142.00 | -93.41 | 560.00 |
|
Cash Flow from Investing Activities
|
-6.34 | -24.49 | 69.76 | -0.48 | -279.00 |
|
Cash from Financing Activities
|
59.73 | 359.29 | -220.37 | 101.47 | -275.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Liquidia Technologies Inc (LQDA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | Elanco Animal Health (ELAN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-31.16 | -159.44 | 14.87 | -63.21 | -2.21 |
|
ROE (%)
|
115.57 | 41.15 | 8.11 | -223.36 | -3.03 |
|
ROA (%)
|
26.48 | -41.39 | 5.52 | -17.39 | -1.30 |
|
EBIT Margin (%)
|
39.06 | -89.09 | 3.17 | -17.57 | 1.61 |
|
Net Margin (%)
|
30.74 | -100.64 | 6.61 | -24.68 | -3.96 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Liquidia Technologies Inc (LQDA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | Elanco Animal Health (ELAN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
2,233.65 | 193.38 | 16.02 | 56.87 | 11.95 |
|
EBIT Growth (%)
|
242.30 | 5.05 | -79.11 | 42.45 | -90.61 |
|
Net Profit Growth (%)
|
197.98 | 10.33 | -58.66 | 22.38 | -145.85 |
|
EPS Growth (%)
|
180.97 | 12.58 | -62.44 | 25.75 | -146.42 |
|
Book Value Growth (%)
|
984.36 | -36.90 | 12.98 | 9.44 | -3.87 |
Valuation Ratios
| Liquidia Technologies Inc (LQDA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | Elanco Animal Health (ELAN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-50.07 | -20.69 | 41.86 | -50.48 | -48.47 |
|
Price / Book Value
|
77.12 | -7.27 | 6.44 | 104.73 | 1.72 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-80.00 | -25.60 | 55.67 | -54.53 | 21.77 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Liquidia Technologies Inc (LQDA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | Elanco Animal Health (ELAN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.63 | -0.77 | 0.00 | 1.42 | 0.58 |
|
Short term debt to equity ratio
|
0.00 | -0.22 | 0.00 | 0.85 | 0.01 |
|
Current Ratio
|
2.31 | 1.23 | 2.86 | 1.43 | 2.05 |
|
Quick Ratio
|
2.12 | 1.17 | 2.77 | 1.34 | 1.10 |
|
Interest Coverage
|
6.61 | -6.86 | -- | -37.09 | 0.36 |
Operating Efficiency Ratios
| Liquidia Technologies Inc (LQDA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | Elanco Animal Health (ELAN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
24.08 | 36.78 | 9.26 | 35.73 | 22.95 |
|
Asset Turnover
|
0.86 | 0.41 | 0.84 | 0.70 | 0.33 |
|
Receivable days
|
65.53 | 52.44 | 28.27 | 104.82 | 70.73 |
|
Inventory Days
|
331.59 | 172.81 | 355.76 | 167.98 | 226.89 |
|
Payable days
|
115.39 | 296.14 | 785.55 | 529.03 | 45.50 |
|
Cash Conversion Cycle
|
281.73 | -70.89 | -401.52 | -256.23 | 252.12 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
